Good day and thank you for standing by. Welcome to the Evaxion Biotech Business Update Conference call. [Operator Instructions] Please be advised, that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Christian Kanstrup, CEO. Please go ahead.

Good morning and good afternoon, everyone. And a very warm welcome to this Evaxion business update conference call on the back of our Q2 results. I'm Christian Kanstrup, CEO of Evaxion. With me today, I have Birgitte Rono, our CSO. I have Jesper Nyegaard Nissen, our COO and CFO. And I also have a new joiner with me today which is Mads Kronborg, VP Investor Relations and Communication. And I would actually like just to start out handing briefly over to Mads for a brief introduction to who you are. This is the first time you are attending the call here.

Thank you, Christian. And thank you for the opportunity. And just for a brief introduction, I have some 15 years of experience in Corporate Communication and Investor Relations from the pharmaceutical and biotech industries, having early held positions like Head of Corporate Communication at Lundbeck and Head of IR and Communication at Zealand Pharma. I'm glad to join Evaxion at this very interesting time for the company with a number of milestones lying ahead and I'm looking forward to help communicate our progress and facilitate the dialogue with you as investors, analysts and journalists. You will find my contact information on the Investors section of our website and are of course always welcome to get in touch.

I am pleased to have Mads on board so we can provide even better service and support to all of you. So great to have you on board, Mads. Then let's jump to the next slide and look at the agenda for today. I'm going to do a brief introduction, then I'll hand over to Birgitte for an R&D business update, Jesper will be covering our financial results. I will conclude before we head into the Q&A part. But before we get going for real, let's just direct our attention to Slide 3, which is forward looking statements. As you know, we will be talking about the future and that do entail uncertainty. Hence please read this one carefully. So with that, let's look at some of the key achievements since last business update. As you know, one of the key elements in our strategy is to create value via a multi-partner approach. And here, I'm super pleased to see that we have been advancing our partnering discussions since our last update. We are seeing solid interest from external parties, both in our AI immunology platform and pipeline candidates. And we do have several partnerships discussions ongoing. And this is, of course, key to execute upon our multi-partner strategy that we see these discussions advancing. What I'm also pleased about is that we are seeing progress on the EVX-01 program. We did present positive and validating Phase 2 immune data at ASCO this year. We also presented our Phase 1 results in a leading medical journal including the 67% objective response rate from the Phase 1 trial, which I'm very proud about. And very importantly, we are on track for a key milestone for Evaxion, our 1-year clinical data readout, which will be presented at the ESMO Congress in September.…

Thank you, Christian. It has been a very active and busy time during the last quarter. And today, I'll focus on the data from the Phase 2 study of EVX-01 presented at ASCO in June and on the improvement on this central building block in our AI immunology platform that we call EvaxMHC. And that building block is key for designing effective vaccines. The improved performance of this building block was presented at the Computational Biology Conference called Intelligent Systems for molecular biology in July. So our EVX-01 lead product candidate is a personalized cancer vaccine designed to engage the patient's own immune system to fight the cancer. And EVX-01 is currently in Phase 2 in a global multicenter trial in first-line advanced melanoma. So the patients enrolled in the Phase 2 trial received standard of care. That is the checkpoint inhibitor from MSD called KEYTRUDA from instead, and they receive it according to label in combination with 6 initial EVX-01 priming doses following by 4 additional booster doses. So EVX-01 consists of 10 AI immunology identified new antigens and new antigens are these short sequences that are exclusive found in tumors. And when administered to a patient, they will induce a specific T-cell response with tumor killing potential. So in June, we presented encouraging immune data from the first 12 patients at ESCO. And what the data demonstrated was that we could find EVX-01 induced T-cell responses in all of these evaluated patients. And the graph to the right displays for EVX-01 induced immune response over time. Week 1 represents baseline where the patients have not received any study therapy, week 12 is where the patients have been dosed with KEYTRUDA. And at week 18, that is during the EVX-01 priming phase, whereas week 30, that is after priming,…

Thank you, Birgitte. I think it's fair to say it's truly exciting to see the EVX-01 data continuing to unfold. So looking forward to September. And now over to you Jesper, to see how the Q2 numbers have been unfolding.

Thank you, Christian. I will focus my comments on the financial results for the first half year of 2024 compared to the first half year of 2023. All the numbers that I will review will be approximate for easy sharing during the call. For additional information regarding our first half year results and period comparisons, please refer to the business update on the second quarter 2024 financial result, press release and the Form 6-Ks we have filed this morning. Starting with our financial highlights for the first half year of 2024, then we are seeing the effects of the 2023 cash spend optimization and organizational slimming in the financial results. This is linked to the continued implementation of the focused company strategy with intensified focus on value realization we are partnering, as we shared at prior calls. As of June 30, 2024, cash and cash equivalents were USD 8 million, we expect that our existing cash and cash equivalents will be sufficient to fund our operation expenses and capital expenditure requirements into February 2025. If all prefunded warrants included in the public offering in February 2024 are exercised, we expect necessary funding will be in place into March 2025. As shared earlier, the company received May 7, 2024, a NASDAQ equity deficiency letter, as a result of our equity being below $2.5 million. A plan to regain compliance have been shared with and accepted by NASDAQ, providing the company until November 4, 2024, to evidence compliance. Looking at our expenses for the period. Research and development expenses were $5.6 million for the 6 months ended June 30, 2024. The decrease of $1.2 million versus the same period in 2023 was primarily due to a decrease in employee-related costs counterbalanced by a smaller increase in costs related to clinical trials. General and administrative expenses were $3.6 million for the 6 months ended June 30. The decrease of $1.7 million versus the same period in 2023 was primarily due to reduced external costs related to professional fees as well as reduced employee costs for the period. Finance income and expenses for the first 6 months of 2024 are primarily impacted by effects from the remeasurement of the derivative liability related to investor warrants from the public offering in February 2024, as well as the private placement in December 2023. These effects have been eliminated going forward as the investor warrants have had their exercise currency change from USD to DKK during Q2, moving them from being recognized as financial instruments to equity instruments. And with this, I would like to turn back to you, Christian, for a few conclusive remarks before the Q&A.

Thank you so much, Jesper, and thanks for the update on the numbers. Let me just quickly provide a few conclusive remarks before we jump into the Q&A part. I think it's fair to say that we are seeing a solid progress on our 3-pronged business model and very good traction along the different parts. Importantly, also, we are having a strong focus on advancing ongoing business development discussions, which, of course, is a key milestone for us this year as well that we will be focusing on value generation via a multi-partner approach. Again, the data Birgitte presented shows that EVX-01 continues to deliver solid data, and we do have a major milestone coming up here at ESMO in September. And in addition to that, it is going to be a big time ahead with several of our other 2024 milestones going to report out, just as we are on track for delivering on remaining milestones during the second half of the year. So all in all, I would say, I am very pleased with the progress we are seeing and strong focus upon execution and bringing our strategy forward. So with that, I would very much like to open up for the Q&A session. So please just join the Q&A session.

Thank you. [Operator Instructions] And the first question comes from the line of Li Chen from H.C. Wainwright. Please go ahead. Your line is now open.

Hey, Li.

Hello everyone. Yeah, hi Christian. Congratulations on this great quarter. I have a couple of questions. First, do we expect any update between the ESMO [ph] data and the final data in 2025 in regards to EVX-01?

I can answer that. Hi, Li. So we are continuously generating more data also on the biomarker side. And yes, we do expect to in early '25 to present some more of that work.

Excellent. Thank you very much. And another question I have is regarding to VX-B2 vaccine. Can you give us a sense of what could be the potential scenario for the next step - with the development with the collaboration with Afrigen?

Yes. I think if we take B2 in general, right, you can say that's, of course, at the preclinical stage. And then it's, I think, especially one of the assets where we are looking for partnering to bring it forward broadly. So the next steps on B2 in general would be partnership discussions for the Afrigen collaboration, in particular, which, of course, is for an mRNA-based version for low and middle-income countries. There, the next step is establishing the preclinical proof-of-concept, which will be presented at this 18th Vaccine Congress in September. And then next steps beyond that, that would depend on, you can say, the data as well. But primarily, this is a research collaboration, focusing on establishing the proof-of-concept for use of the two B2 antigens in an mRNA construct.

Got it. Maybe if I can squeeze in my last question. Can you give us a sense of the current status of the ERV [ph] platform, what kind of preclinical data you are generating? When do we see the data published or being announced? Thank you.

Are you thinking in particular for the precision-based vaccine, where we have the milestone or I think in more ERVs in general?

I think you stated the updated time line second half of '24.

Yes.

Yes, that's the one I'm talking about.

So the milestone later this year is or relates to the precision version of the vaccine. So, meaning that we are currently developing a vaccine that fits a broader subset of patients with a certain indication, so not personalized as such. And we're currently doing a lot of design studies and also preclinical evaluation of these designs to be ready for presentation at the conference later this year.

And I would say, personally, I'm super excited about the whole -- first of all, ERV as a novel cancer target, but also the concept of developing a precision vaccine where you have the opportunity of reaching new patients, which you might not be able to reach with standard immunotherapy and or with the personalized cancer vaccine due to a lower tumor mutational burden. So we are looking forward to seeing the data here later on this year.

Thanks very much. Looking forward to the data.

Thank you. We will now the next question. Please stand by. And the next question comes from the line of Thomas Flaten from Lake Street Capital Markets. Please go ahead. Your line is now open.

Hey, Thomas.

Hey, thank you for taking the questions. Christian, I was wondering if you could maybe characterize the partnership discussions that you mentioned in the press release that are ongoing. Are they infectious disease-focused, like cancer focus maybe across the board? How advanced are those conversations? Just a little bit more color there would be super helpful.

Yeah. No, I would say, Thomas, without, of course, being able to go into a whole lot of detail, it's across the board. And that's also what I tried to say here. We are seeing interest both in AI immunology, i.e., in, you could say, new target discovery collaborations like the one we have with MSD, but we're definitely also seeing interest in our pipeline assets, which is both from the cancer side and from the infectious disease side. And I would say some of these discussions are fairly advanced, which they also need to be given that we keep the milestone of the USD 14 million in BD income this year because it, of course, takes time to get deals done. So I would say we have a good mix of things which are quite advanced and across the board as well as new things coming in, which would probably more likely be 2025 deals. So I think given the fact that we only really started very active in our BD efforts in say, towards the end of the first quarter, then I am very pleased with where we are now in the pipeline of deals and seeing that it is a broad-based interest.

And then given where your spending was, particularly in R&D for the second quarter, can you help us think through how we should model spending, particularly in R&D for the second half of the year, given where you are with cash and the cash runway you've laid out?

Yes. I think you should be looking at slightly lower R&D spend in the second half of the year. And actually, the same goes for G&A. So we will be having a lower second half spend than first half. And also, you can say, from a cash out point of view, I mean, we are paying insurance. We are paying employee bonus, et cetera, in Q1. So the cash flow is also skewed towards the first half of the year. So definitely looking at lower R&D as well as G&A in the second half and also lower cash out.

Excellent. I appreciate you taking the questions. Thank you very much.

Thank you. [Operator Instructions] And the next question comes from the line of Chong Liu from Ladenburg. Please go ahead. Your line is now open.

Hey, Chong.

Hello. This is Chong for Ahu Demir. We have a question regarding the upcoming results at ESMO. So could you please give us more color on what we will expect to see? And besides the immunogenic [ph] data, are we also expecting to see the update ORR PFS or OS? Thank you.

Yes. Thank you for that question. So we will present 1-year clinical readout from the Phase 2 study, and we will also present more biomarker analysis, including a few more cases of patients that have been boosted. And the exact data, the exact clinical data, we cannot say that yet exactly what it's going to be because we are a little bit reluctant to conclude on the primary endpoint when it's a preliminary readout.

But it is going to be clinical data that we will be...

Clinical data. So of course, this is criteria and the response of the clinical of their responses.

And so my next question is, will this Phase 2 data readout help you advance maybe into the next stage of the partnership discussion in the future?

I think the short answer to that is, yes, of course, assuming it's good data, which we hope and expect. But no, there's no doubt that, I mean, when you are discussing personalized cancer vaccines, I think given this is a novel concept, then clinical data are important in partnering discussions, and that's also why this is an important milestone for us in that respect. So yes, it will be very important.

Okay. And my next question is regarding the EVX-B3. So can you please provide some updates for that?

Yes. So EVX-B3 is a collaboration with MSD on an undisclosed pathogen vaccine and it's running according to contract, meaning that we have now signed the antigens. We have produced them, and we are currently testing them in animal models. So we are on track with that collaboration.

And then that is set to, you can say this first phase on the testing is set to conclude during the second half year. And then we will be discussing with MSD. Next phase, which would be a more traditional license and collaboration structure, of course, assuming that the data looks promising.

Okay. And my last question is, so what is the difference of the EDEN new model version, like 5.1 from the old version?

Yes. You can say the overarching objective with the upgrade is, of course, to increase the predictive capabilities of EDEN, making us capable of identifying and - with the greater certainty identifying the right antigens but also possibly discovering targets which could not be discovered in other ways. And we've been doing a couple of things. We've been expanding the training data set. What we have done is we have acquired additional training data from public sources using what we call retrieval augmented generation with large language models, and that has been followed by a manual domain expert curation. And this enhanced data set now includes the prediction of bacterial toxins, which is a new feature in EDEN 5.0. Also, we have called advanced protein feature prediction. We developed a completely new building block for protein feature prediction, and we have fine-tuned the protein language model, thereby enhancing the model's capability to predict various protein characteristics. And then all of this, I mean, as I said, about improving the antigen identification, we have trained a new machine learning model in EDEN specifically designed to identify antigens improving both the, you could say, accuracy and the reliability of the antigen prediction. So I mean, in short, improving the predictive capabilities of EDEN, which is a continuous process that we're doing with all our AI models both by taking a detailed focus on the individual model but also as Birgitte presented on the EvaxMHC building block, which is used across the models, improving that and hence, thereby improving the predictive capabilities of all models together. So we're definitely looking forward to presenting that in greater detail at the ECCB conference in September.

And so are you going to apply this new model to any programs?

I mean, that's, of course, going to be applied to possible new target collaboration, discussions or collaborations with pharma biotech, as well as our own internal programs that we are looking to bring forward. We have a list of infectious disease targets that we would like to bring forward as well. And of course, there, this EDEN 5.0 will be a great help in quickly advancing new candidates into our internal pipeline, as well as it will be additional value proposition towards external parties when we collaborate with them.

Great. Thank you.

Thank you. As there are no further questions, I would now like to hand back to Christian Kanstrup for any closing remarks.

Thank you so much. I just want to say thank you to all of you either dialing in or joining the webcast. And also thank you so much for the question. We also always appreciate a good dialogue. So thank you so much for that. And now we are looking forward to be reporting on the key milestones ahead in parallel with advancing the different discussions that we have ongoing. So thank you so much to all of you for listening in.

Thank you. This concludes today's conference call. Thank you for participating. You may now disconnect.